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Sterol 27-hydroxylase is important for the degrada-
tion of the steroid side chain in conversion of choles-
terol into bile acids and has been ascribed a regulatory
role in cholesterol homeostasis. Its deficiency causes the
autosomal recessive disease cerebrotendinous xantho-
matosis (CTX), characterized by progressive dementia,
xanthomatosis, and accelerated atherosclerosis.
Mice with a disrupted cyp27 (cyp272/2) had normal
plasma levels of cholesterol, retinol, tocopherol, and
1,25-dihydroxyvitamin D. Excretion of fecal bile acids
was decreased (<20% of normal), and formation of bile
acids from tritium-labeled 7a-hydroxycholesterol was
less than 15% of normal. Compensatory up-regulation of
hepatic cholesterol 7a-hydroxylase and hydroxymethyl-
glutaryl-CoA reductase (9- and 2–3-fold increases in
mRNA levels, respectively) was found. No CTX-related
pathological abnormalities were observed. In CTX,
there is an increased formation of 25-hydroxylated bile
alcohols and cholestanol. In bile and feces of the
cyp272/2 mice only traces of bile alcohols were found,
and there was no cholestanol accumulation.
It is evident that sterol 27-hydroxylase is more impor-
tant for bile acid synthesis in mice than in humans. The
results do not support the contention that 27-hydroxyl-
ated steroids are critical for maintenance of cholesterol
homeostasis or levels of vitamin D metabolites in the
circulation.
Sterol 27-hydroxylase is a mitochondrial species of cyto-
chrome P-450 with a broad tissue and organ distribution and
with a broad substrate specificity (for a review, see Ref. 1). The
enzyme is important for bile acid biosynthesis but has also been
ascribed a role in connection with cholesterol removal from
extrahepatic tissues, in regulation of cholesterol homeostasis,
and in metabolism of vitamin D.
Sterol 27-hydroxylase is responsible for the first step in the
degradation of the steroid side chain in connection with bile
acid biosynthesis in the liver. In the major pathway to bile
acids in mammalian liver, 7a-hydroxylation of cholesterol is
the first and rate-limiting step, and 27-hydroxylation occurs at
a later stage with a 7a-hydroxylated intermediate as substrate.
In an alternative pathway, 27-hydroxylation of cholesterol is
the first step in the sequence, followed by a 7a-hydroxylation
catalyzed by a specific oxysterol 7a-hydroxylase (1). In a re-
cently discovered minor pathway, extrahepatic sterol 27-hy-
droxylase converts cholesterol into 27-hydroxycholesterol or
3b-hydroxy-5-cholestenoic acid (2, 3). The latter compounds are
transported to the liver and converted into bile acids.
Sterol 27-hydroxylase has also 25-hydroxylase activity to-
ward vitamin D (4) and 1a-hydroxylase activity toward 25-
hydroxyvitamin D (5). Since there is also a microsomal cyto-
chrome P-450 that catalyzes 25-hydroxylation of vitamin D (6),
the relative importance of the sterol 27-hydroxylase is not
known.
27-Hydroxycholesterol, formed from cholesterol by the sterol
27-hydroxylase, is a potent down-regulator of cholesterol syn-
thesis in cultured cells (for reviews see Refs. 7 and 8). On the
basis of this, and on the basis of studies with sterol 27-hydrox-
ylase inhibitors, sterol 27-hydroxylase has been suggested to
have a regulatory role in cholesterol homeostasis. The relative
importance of this mechanism is controversial, however. Based
on studies with cholesterol specifically deuterium-labeled in
the 27-position, which retards the rate of 27-hydroxylation, we
showed that sterol 27-hydroxylase activity is of little or no
direct importance for cholesterol-induced suppression of cho-
lesterol synthesis in mouse liver (9).
It is now well documented that patients with the rare disease
cerebrotendinous xanthomatosis (CTX)1 have a deficiency of
sterol 27-hydroxylase (for a review, see Ref. 10). Recently, a
number of mutations have been defined in the sterol 27-hydrox-
ylase gene of these patients (11–20). As a result of the enzy-
matic defect, patients with CTX have a reduced synthesis of
bile acids, in particular chenodeoxycholic acid (10). Cholic acid
is formed in these patients by a pathway involving 25-hydroxy-
lated bile alcohols as intermediates. Under normal conditions
this alternative pathway is of little or no importance, both in
rats and man (21, 22). Due to the reduced formation of bile
acids, the negative feedback of the cholesterol 7a-hydroxylase
is reduced, resulting in an up-regulation of this enzyme. As a
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consequence, gram amounts of bile alcohols are formed and
excreted in bile and feces. Another consequence of the disease
is excess formation and accumulation of cholestanol (10). Most
of this formation seems to be secondary to the accumulation of
an intermediate in bile acid biosynthesis, 7a-hydroxy-4-cho-
lesten-3-one. This steroid can be converted into cholestanol by
hepatic enzymes.
Patients with CTX have normal cholesterol levels in the
circulation (17). Despite this they develop xanthomas and pre-
mature atherosclerosis. The possibility has been discussed that
this may be due to the reduced elimination of cholesterol from
macrophages by the sterol 27-hydroxylase (1–3).
Disturbances in vitamin D metabolism have been described
in a few cases of CTX (23), but this does not seem to be a
general finding.
Studies on patients with CTX have provided important in-
formation about the role of the sterol 27-hydroxylase in man.
The importance of this enzyme for bile acid formation, choles-
terol homeostasis, and vitamin D metabolism may, however, be
different in different species. A lack of an enzyme may activate
compensatory mechanisms that may be different in different
species. In order to evaluate further the role of the sterol
27-hydroxylase in mammals, we have produced and character-
ized mice deficient of the enzyme.
EXPERIMENTAL PROCEDURES
Cloning of the Mouse cyp27 and Construction of the Targeting Plas-
mid—Oligonucleotides complementary to the putative exon 3 of the rat
cyp27 were prepared (24–26). Oligonucleotides e (59-AGGACAGCAGT-
GGTACCATCTGCG-39) and f (59-CTTCCAAGGCAAGGTGGTAAA-
GAAGA-39) were used to amplify 197 bp containing the putative mouse
exon 3 (Fig. 1). The PCR product was used to probe a mouse 129SV
Genomic Library (Lambda Fix2, Stratagene, La Jolla, CA). A positive
clone designated 24(1), which includes 13.1-kb mouse cyp27 gene se-
quences, was isolated. A targeting construct was made to replace a
71-bp BamHI fragment in exon 8 with a neo sequence (see Ref. 27, Fig.
1). To do so, a 7-kb BamHI fragment, which includes sequences homol-
ogous to the human CYP27 exons 2–8, was subcloned into a unique
BamHI site of the pPNT plasmid and designated pPNT-7. A 1.1-kb
BamHI/NotI fragment, which includes the 39 end of the putative exon 8,
exon 9, and the 39-untranslated sequences, was purified from clone
24(1), subcloned into pSC301 plasmid, and designated pSC301-S. The
BamHI/SalI 1.1-kb band of pSC301-S was then subcloned into the
pPNT-7 plasmid that was previously digested by XhoI/NotI to make
pCYP27T1. In the targeting construct the deletion of a 71-bp fragment
from the putative mouse cyp27 exon 8 is located upstream to the
putative heme-binding site, highly conserved in human (28) and rabbit
(29), and crucial for the activity of P-450 enzymes (30). For verification,
the junctions between the neo and the cyp27 sequences were sequenced
and compared with the published cyp27 rat cDNA (24).
Gene Targeting and Screening of the Homologous Recombinants—
The targeting plasmid was linearized by cleavage with NotI. ES cell
cultures and electroporations were performed as described (31). Ten to
twelve days after electroporation, colonies resistant to 200 mg/ml G418
and to 2 mM ganciclovir (Syntex, Palo Alto, CA) were picked and pas-
saged in clonal fashion. To screen the cells with correct targeting, a
probe that identifies the 1.1-kb short arm was prepared by PCR using
oligonucleotide a (59-TGGTTCCCACAAACTCCCGGATCAT-39), which
is complementary to the putative rat 59 exon 7 sequences, and oligonu-
cleotide T3, which is complementary to the vector short arm sequence.
Southern blot analysis resulted in identification of a 9- and a 12-kb XbaI
fragment for the targeted and for the non-targeted alleles, respectively.
To verify the planned disruption of the gene, a probe from the putative
mouse exon 3 was prepared and used in Southern blotting to identify a
5- and a 16-kb XbaI fragment from the targeted and non-targeted
alleles, respectively (Fig. 2a).
Generation of Germ Line Competent Chimeras and Mouse Breeding—
Approximately 10 ES cells were injected into the blastocyte cavity of
C57BL/6J embryos. Surviving blastocytes were transferred to the uteri
of pseudo-pregnant CD-1 females. An average of two to three transfers
were made per cell line. Chimeric animals were further bred to
C57BL/6J animals to determine their germ line competency. F1 ani-
mals heterozygote for the cyp27 disruption were crossed to produce mice
homozygote to the knock-out cyp27.
PCR Genotyping of the F2 Siblings—To genotype the F2 siblings, a
double PCR reaction was performed. PCR was carried out using oligo-
nucleotide a (59-TGGTTCCCACAAACTCCCGGATCAT-39) mapped to
the 59 end of the putative exon 7, oligonucleotide b (59-CCATAGC-
CAAAGGGCACAGAGCCAA-39) mapped to the 39 end of the putative
exon 8, and oligonucleotide c (59- ATCGCATCGAGCGAGCACGTACT-
39) complementary to neo sequences (Fig. 1). The PCR products of the
targeted allele and the normal gene were 1- and 0.3-kb, respectively. To
avoid the out competition of the 1-kb by the 0.3-kb PCR product, a triple
amount of oligonucleotide a was used. The PCR conditions were as
follows: denaturation for 5 min at 94 °C followed by 35 cycles of 94 °C
for 1 min, 65 °C for 1 min, and 75 °C for 1 min. To avoid PCR artifacts
in genotyping, two additional, independent, reactions were carried out
to identify the targeted allele and the normal allele. The oligonucleo-
tides used for these reactions were c and d (59-CCACCATGATATTCG-
GCAAGCAGG-39, and a and b, respectively) (Fig. 3).
RNA Blot Analysis—For visualization of cyp27 mRNA the following
protocol was used. RNA was extracted from mice livers using Trizol
reagent (Life Technologies, Inc.), quantified by spectrophotometry and
visualized following electrophoresis on a 1.5% agarose gel stained by
ethidium bromide. Twenty mg of total RNA were loaded on a 1.6%
agarose gel, electrophoresed, and blotted as described (32). The blots
were hybridized using a mouse cyp27 exon 3 or a Syrian Hamster
HMG-CoA reductase cDNA probe labeled by nick translation (Life
Technologies, Inc.).
For visualization and quantification of cyp7 mRNA the following
protocol was used. Total cellular RNA was isolated with the Ultra-
specTM RNA Isolation System (Biotecx Laboratories, Houston, TX).
Electrophoresis of total RNA and poly(A)1 RNA in agarose gels con-
taining formaldehyde and blotting of the separated RNA onto nylon
membranes (Hybond, Amersham Pharmacia Biotech, UK) was carried
out by standard procedures (33). For the hybridization, cDNA probes for
the rat cyp7 and human actin were used, labeled with 32P with the use
of Pharmacia Oligolabeling kit (Amersham Pharmacia Biotech, Upp-
sala, Sweden). Hybridization was according to Gehring et al. (34). The
blots were exposed to Fuji New x-ray films at 270 °C. Semi-quantita-
tive analysis of the relative amount of mRNA was estimated by
densitometry.
Immunoblot Analysis—Livers were homogenized in a lysis buffer
containing 20 mmol of Tris-HCl, pH 7.7, 1 mmol of EDTA, and 0.25 M
sucrose and centrifuged at 1000 3 g for 5 min. The supernatant was
precipitated at 5000 3 g for 10 min and the mitochondrial fraction
resuspended in the lysis buffer. The proteins were quantified using the
Bio-Rad protein assay (Bio-Rad, Munchen, Germany). A total of 75 mg
of protein was loaded on a 10% SDS-polyacrylamide gel and electro-
phoresed for 12 h at 15 mA. Electroblotting to cellulose nitrate
(Schleicher & Schuell, Dassel, Germany) was carried out overnight at
20 V. Blocking of the membrane was carried out in a buffer containing
1.34 M NaCl, 0.03 M KCl, and 0.25 M Tris (TBS buffer) for 5 h at 4 °C.
Incubation with primary polyclonal antibody directed against the
mouse sterol 27-hydroxylase, extracted from rabbit serum (a gift from
Dr. David W. Russell), was diluted 1/1000 in the blocking buffer (TBS)
that also contained 0.05% Nonidet P-40 (Sigma). Incubation was carried
out overnight at 4 °C. The filter was washed four times for 15 min each
in a TBS buffer containing 0.1% SDS, 0.1% Nonidet P-40, and 0.5%
deoxycholic acid sodium salt (Sigma-Aldrich Chemie, GmbH). Incuba-
tion with 1/2000 secondary antibody, anti-rabbit IgG horseradish per-
oxidase-linked whole antibody from donkey (Amersham Pharmacia Bio-
tech, Buckinghamshire, UK) was carried-out for 2 h at room
temperature. Development was carried out using the Amersham ECL
detection reagents (Amersham Pharmacia Biotech, Buckinghamshire,
UK). The film was exposed for 3 s and developed.
Pathological Analysis—Animals were maintained at the Hadassah-
Hebrew University animal facility in a specific pathogen-free unit.
Breeding pairs were set up to provide normal heterozygote and homozy-
gote siblings of the targeted cyp272/2 mice. Weaning was carried out at
the age of 3 weeks. The animals were genotyped and grouped. Each
group consisted of four to six male littermates. At the end of the
experiment the animals were sacrificed, and their plasma and bile were
collected and gross pathology and histology were performed.
For histological processing the tissue specimens were fixed in 10%
buffered formalin, dehydrated, and paraffin-embedded. Sections 2- to
3-mm thick were cut with a microtome (Leica RM2155, Germany). The
sections were deparaffinized and rehydrated before hematoxylin/eosin
and van Gieson’s elastica stainings and periodic acid-Schiff reaction for
examination in a light microscope (Olympus, Tokyo, Japan). Van Gie-
son’s elastica was used for combined staining of elastic substrates and
connective tissue. After rehydration, the sections were stained for 15
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min in 0.5% resorcine/fuchsin solution in 70% ethanol. Thereafter, the
sections were rinsed in distilled water, differentiated in 96% ethanol,
and transferred to Weigert’s iron-hematoxylin (nuclear staining) for 10
min. The sections were rinsed in distilled water, differentiated in HCl/
ethanol, and rinsed in tap water for 30 min. In a third step the sections
were stained in a picric acid/thiazine red mixture (10:0.2) for 10 min,
rinsed in distilled water containing picric acid, and dehydrated and
coverslipped by an automated coverslipper (Sakura). Periodic acid-
Schiff reaction was used to demonstrate poly- and mucopolysaccharides
and muco- and glycoproteins. After rehydration the sections were put
into 0.5% periodic acid for 5 min at room temperature, rinsed in dis-
tilled water, and transferred to fuchsin/sulfurous acid (15 min at room
temperature). The sections were washed three times in 2
2 water, tap
water (5 min), counterstained with hemalaun, rinsed in tap water,
dehydrated, and coverslipped as described above. Heart and aorta were
processed separately for lipid staining with Sudan III. The heart was
taken out, fixed in 10% buffered formalin for at least 48 h, incubated at
37 °C in 5% gelatin for 2.5 h, in 10% gelatin for 2.5 h and in 20% gelatin
overnight. The hearts were put into a gelatin block and frozen in
isopentane (235 °C) for further processing in a cryostat (Leica,
Frigocut). In brief, the hearts were cut in 10-mm thickness until the
3-valve cusps at the junction of the aorta to the heart and an aorta that
was round in shape was seen. Several sections were taken at this level,
stained with Sudan III, and counterstained with hemalaun. The sec-
tions were examined under a light microscope. The whole aorta was
fixed in 10% buffered formalin, rinsed in tap water, cut open, blocked
with needles, and stained with Sudan III. The aortas were examined for
atherosclerotic plaques. A total of six animals were examined by Pa-
thology Associates Int. (Frederick, MD, project no. 3116-101 and 97-
111-09), and 18 mice were analyzed at the Max-Delbrück-Center (Ber-
lin, Germany).
Vitamin Analysis—Vitamin A and vitamin E levels were analyzed by
high pressure liquid chromatography as described (35). 25-Hydroxyvi-
tamin D was analyzed by a radioimmunoassay (36) using a kit from
Nichols Institute Diagnostics. The accuracy of this method has been
ascertained by a method based on isotope dilution-mass spectrometry
(37). 1,25-Dihydroxyvitamin D was analyzed with a radioreceptor
method (38) using a kit from Incstar (Incstar Corp., Stillwater, MN).
Lipid and Steroid Analysis—Cholesterol and triglycerides in serum
were analyzed with standard enzymatic photometric methods with use
of commercial kits (Boehringer Mannheim, Germany). Cholesterol in
feces was analyzed by isotope dilution-mass spectrometry with 2H6-
labeled cholesterol as internal standard (39). Cholesterol levels in tis-
sue extract were analyzed by the same method. The tissues were frozen
in liquid nitrogen, pulverized mechanically, and extracted with chloro-
form/methanol (2:1, v/v). In both cases, a hydrolysis step was included,
and thus the method detects both free and esterified cholesterol. Oxys-
terols (7a-hydroxycholesterol, 24-hydroxycholesterol, and 27-hydroxy-
cholesterol in serum and in various organs) were analyzed by isotope
dilution-mass spectrometry with use of deuterium-labeled internal
standards as described previously (40). The procedure includes a sa-
ponification step and thus the method includes both free and esterified
steroid. The interassay variation in this assay is below 5% (40).
Bile Acid Analysis—Hydrolyzed bile acids in bile and in feces were
analyzed by combined gas chromatography under the conditions de-
scribed previously (41) using a Hewlett-Packard 5970 mass specific
detection instrument equipped with a 0.33-mm phase HP-ultra 1 col-
umn. All samples were hydrolyzed prior to extraction, methylated with
diazomethane, and trimethylsialylated prior to analysis (41). The sam-
ples were analyzed by the repetitive scanning method for identification
of all bile acids present in the samples (cf. Fig. 5). In addition cholic acid,
chenodeoxycholic acid, deoxycholic acid, and lithocholic acid were quan-
titated by isotope dilution-mass spectrometry with use of deuterium-
labeled internal standards and selected ion monitoring as described
previously (41). The other bile acids were quantitated from the chro-
matogram (total ion current) obtained in the analysis of material to
which no internal deuterated standards had been added (Fig. 5). The
peak area of the trihydroxy bile acids was compared with the peak area
of cholic acid. The amount of cholic acid had been quantitated by isotope
dilution-mass spectrometry in a separate analysis as described above.
The peak area of the dihydroxy bile acids was compared with the peak
area of deoxycholic acid. Deoxycholic acid had been quantitated by
isotope dilution-mass spectrometry in a separate experiment. In a few
cases the gas chromatographic peak was found to contain contaminat-
ing interfering compounds (this was the case in the assay of the small
amounts of some muricholic acid isomers in the material from the
cyp272/2 mice). In these cases a specific ion at m/z 195, specific for
6-hydroxylated bile acids, was used for assay.
Unhydrolyzed bile acids in bile and urine were analyzed by electro-
spray mass spectrometry using a Quattro triple quadropol mass spec-
trometer (Fig. 4). The general conditions used for pretreatment and
analysis were similar to those used for analysis of bile acids by fast
atom bombardment-mass spectrometry (42) The samples (a few ml of
bile and 40–300 ml of urine) were diluted with water to a 1-ml volume
and applied to Sep-Pak C18 columns (Waters, Milford, MA). The col-
umns were washed with water (5–10 ml) and eluted with methanol (2
ml). After evaporation of the solvent, the samples were dissolved in
acetonitrile/distilled water (1:1, v:v). Of this solution 10 ml was intro-
duced into the mass spectrometer via loop injection with acetonitrile/
water as mobile phase.
Assay of Lathosterol—This assay was performed with isotope dilu-
tion-mass spectrometry and utilization of deuterium labeled lathosterol
as internal standard as described previously (43).
Experiments with 7b-3H-Labeled 7a-Hydroxycholesterol—7b-3H-la-
beled 7a-hydroxycholesterol with a specific radioactivity of 70 3 106
cpm/mg was synthesized as described previously (44). The steroid,
about 9 3 106 cpm, was dissolved in 0.2 ml of ethanol, and this solution
was added to 1 ml of 0.9% NaCl (w/v) containing 1% bovine serum
albumin (w/v). The solution was injected intraperitoneally in one
cyp271/1 and one cyp272/2 mouse. Feces was collected during three
24-h periods after this injection. The different fecal portions were re-
fluxed with ethanol for 24 h. The ethanol was evaporated, and the
material was hydrolyzed with KOH in aqueous ethanol (41). The hy-
drolyzed alkaline material was diluted with water and extracted three
times with hexane. After acidification with diluted HCl, the water
phase was extracted three times with diethyl ether. Radioactivity was
measured in aliquots of the hexane phase containing neutral steroids
and of the ether phase containing bile acids.
RESULTS
Cloning of the Mouse cyp27 and Construction of the Target-
ing Plasmid—Southern blot analysis on genomic DNA ex-
tracted from SV129 female mice resulted in a partial restriction
map of the mouse cyp27 and revealed the presence of a single
copy gene (data not shown). We disrupted the cyp27 gene by
inserting the neo gene and deleting 71-bp BamHI fragment
from exon 8 (Fig. 1b) which is adjacent to the putative heme-
binding site. Electroporation of the targeting vector to ES cells
resulted in colonies from which extracted DNA revealed a
;5-kb fragment that corresponded to the targeted allele by
Southern blot analysis (Fig. 2a). These cells were used to es-
tablish cyp27 knock-out mice (Figs. 1c and 2a). Northern blot
analysis of RNA extracted from wild type and mutant mice
revealed a 1.9–2.4-kb band in the normal mice and 3.9-kb band
in the homozygote cyp272/2 animals (Fig. 2b). Immunoblot
analysis revealed no immunoprecipitable protein in the ho-
mozygote mice (Fig. 2c). Mutant mice were generated and
genotyped by using three independent PCR reactions (Fig. 3).
Pathological Analysis—At the age of 3 weeks, the mice were
weaned, and at the age of 4 weeks littermates in groups of 4–6
animals were allocated to the different cages. A total of 18
animals were used for these experiments and were fed a nor-
mal chow diet for 3 or 6 months. In general, all animals gained
weight and behaved normally. No gross abnormalities were
detected. Also a detailed histological analysis of all major or-
gans and the vascular system revealed no abnormal findings.
Diffuse hepatocytic cytoplasmic pallor grade 2–3 was observed,
which is a normal finding in well-nourished animals.
Formation of Bile Acids in cyp272/2 Mice—With the use of
combined gas chromatography-mass spectrometry as described
under “Experimental Procedures,” the concentration of bile
acids in a sample of hydrolyzed bile from a cyp272/2 mouse was
found to be only about 0.9 mg/ml as compared with about 8
mg/ml in a sample from a cyp271/1 mouse. As shown in Table
I, cholic acid was the dominating bile acid, and the amount of
trihydroxy bile acids was almost 20-fold higher than the
amount of dihydroxy bile acids in both bile samples.
The alkaline hydrolysis used in the above analysis does not
cleave sulfate esters and does not give information about the
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type of conjugates present in the bile. In order to get qualitative
information about the type of conjugates, samples of unhydro-
lyzed bile from a cyp271/1 and a cyp272/2 mouse were also
analyzed by electrospray mass spectrometry. As shown in Fig.
4, the major peak both in the analysis of the cyp271/1 and in
the analysis of the cyp272/2 appeared with a m/z at 514,
corresponding to taurine conjugate of trihydroxy bile acids. In
addition, there was a minor peak at m/z 498, corresponding to
taurine conjugate of dihydroxy bile acids. In the analysis of the
bile sample from the cyp272/2 mouse, small peaks also ap-
peared at m/z 531 and m/z 545. Most likely, these peaks
correspond to sulfate ester of dihydroxy bile acid and monodi-
hydroxy bile acid. Interestingly, trace amounts of compounds
with m/z 611, 627, and 643 were present in the bile sample
from the cyp272/2 mouse. These peaks correspond to quasimo-
lecular ions of glucuronides of bile alcohols containing 27-car-
bon atoms and four, five, and six hydroxyl groups (42). No such
compounds could be detected in the analysis of the bile sample
from the cyp271/1 mouse.
That the production of bile acids was markedly decreased in
the cyp272/2 mice was also confirmed by combined gas chro-
matography-mass spectrometry of feces obtained from four
cyp271/1 and four cyp272/2 mice (Fig. 5 and Table I). As shown
in Table I, the excretion of bile acids in feces was about 78 mg/g
in the cyp272/2 mouse and about 430 mg/g in the cyp271/1
mouse. The composition of the fecal bile acids was similar in
the two groups, although the relative amount of dihydroxy bile
acids was somewhat higher in the cyp272/2 group (about 50%)
as compared with the cyp271/1 group (about 30%).
Bile acids in feces were also analyzed in a cyp271/2 mouse.
The amount of bile acids (about 400 mg/g feces) as well as the
composition was very similar to those found in feces of cyp271/1
mice.
In order to further ascertain that there is a reduced forma-
tion of bile acids in cyp272/2 mice, one cyp272/2 mouse and one
cyp271/1 mouse was injected with the same amount of 7b-3H-
labeled 7a-hydroxycholesterol. Since 7a-hydroxycholesterol is
an intermediate in bile acid biosynthesis occurring after the
rate-limiting step, a rapid formation of bile acids from this
compound can be expected in normal mice. In accordance with
this, 1.6 3 106 cpm were found in the bile acid containing ether
extract of the feces collected during 72 h after the injection of
9 3 106 cpm in the cyp271/1 mouse. The hexane extract con-
taining neutral steroids contained 0.4 3 106 cpm. Only 0.2 3
106 cpm were found in the bile acid containing extract from the
cyp272/2 mouse and 1.0 3 106 cpm in the extract containing
neutral steroids. The formation of radioactive bile acids from
7b-3H-labeled 7a-hydroxycholesterol in the cyp272/2 mouse
FIG. 1. Construction of the targeting plasmid. Schematic representation of exons 2–9, and the location of the restriction sites for BamHI (B),
XbaI (X), as well as the neomycin (neo) and the thymidine kinase (TK) sequences are shown. The probe used for screening the library and Southern
blot analysis is shown (probe). Oligonucleotides used for PCR-based genotyping (a–d) and oligonucleotides used for preparing the probe (e and f)
are also shown.
FIG. 2. Verification of the cyp27 disruption. a, Southern blot
analysis of DNA obtained from ES cells of non-targeted cells (1) and
targeted cells (2). M, molecular weight marker, bacteriophage l DNA
digested with HindIII restriction endonuclease. b, blot analysis of RNA
obtained from livers of control (1) and homozygote (2) mice. M, molec-
ular weight marker, Kodak IB 76200 (Eastman Kodak), the location of
the migration of ribosomal RNA is shown. Quantification (1 mg/lane) is
verified using ethidium bromide staining (lower panel). c, immunoblot-
ting of total liver mitochondrial protein obtained from control mouse (1)
and from a homozygote mouse (2) with polyclonal antibody is shown.
The lower panel represents Ponceau (Sigma) staining of the filter used
for hybridization and reveals the presence of similar quantities of
protein in both lanes.
FIG. 3. PCR-based genotyping. Lanes 1–3 represent the results of
a PCR reaction that included oligonucleotides a, b, and c (Fig. 1c).
Oligonucleotides a and b amplify the normal allele and a and c the
targeted allele. Lanes 4–6 represent the results of PCR amplification of
the targeted allele only, using oligonucleotides c and d (Fig. 1c, neo
sequences). Lanes 7–9 represent the results of PCR amplification of the
wild type allele only, using oligonucleotides a and b (Fig. 1c). M, mo-
lecular weight marker; f X, HaeIII-digested DNA. The results for the
wild type (WT) and targeted (T) alleles are shown.
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was thus only about 13% of that in the cyp271/1 mouse. It
should be pointed out, however, that due to the expanded pool
of 7a-hydroxycholesterol in the cyp272/2 mice (Table III), the
conversion of the trace amount of labeled intermediate may not
be an adequate reflection of the conversion of the endogenous
compound.
The possibility that bile acids were excreted in urine was also
tested with electrospray mass spectrometry of un-hydrolyzed
urine samples from cyp271/1 and cyp272/2 mice. No significant
amounts of bile acids were seen. Small peaks at m/z 627, 643,
and 657 were seen in the analysis of urine from cyp272/2 mice
but not from cyp271/1 mice. The latter peaks are likely to be
due to glucuronides of bile alcohols containing 27 carbon atoms
and five, six, and seven hydroxyl groups (42) (cf. above).
The low production of bile acids is likely to result in an
up-regulation of the cholesterol 7a-hydroxylase due to a re-
duced negative feedback suppression of this enzyme. In accord-
ance with this, the concentration of 7a-hydroxycholesterol in
the liver, the kidney, and the brain was markedly higher in the
cyp272/2 mice than in the cyp271/2 and in the cyp271/1 mice
(Table II). It is well established that circulating levels of 7a-
hydroxycholesterol reflect the activity of the cholesterol 7a-
TABLE I
Analysis of fecal and biliary bile acids in wild type and cyp272/2 mice
Bile acid
Fecal bile acids Biliary bile acids
1/1 2/2 1/1 2/2
mg/g fecesa mg/ml bileb
3a-Hydroxy-5b-cholanoic acid (lithocholic acid) (I) 20 6 5 2 6 1 ,0.01 ,0.01
Unknown 3,12-Dihydroxycholanoic acid (II) 22 6 3 5 6 2 n.d. n.d.
3a,12a-Dihydroxy-5b-cholanoic acid (deoxycholic acid) (III) 91 6 11 26 6 8 0.29 0.02
3a,6b,7a-Trihydroxy-5b-cholanoic acid (a-muricholic acid) (IV) 44 6 14 10 6 6 0.82 0.02
3a,7a-Dihydroxy-5b-cholanoic acid (chenodeoxycholic acid) (V) 4 6 1 0.9 6 0.1 0.19 0.03
3a,7a,12a-Trihydroxy-5b-cholanoic acid (cholic acid) (VI) 27 6 4 14 6 1 5.67 0.70
3,12-Dihydroxycholanoic acid (VII) 18 6 6 7 6 3 n.d. n.d.
3a,6b,7b-Trihydroxy-5b-cholanoic acid (b-muricholic acid) (VIII) 63 6 9 0.8 6 0.8 0.60 0.05
3a,6a,7b-Trihydroxy-5b-cholanoic acid (v-muricholic acid) (IX) 112 6 18 10 6 2 0.22 0.05
Unknown 6-hydroxylated trihydroxycholanoic acid (X) 29 6 4 4 6 2 n.d. n.d.
430 6 55 78 6 18c 7.79 0.87
a Mean 6 S.E., n 5 4.
b Results are given from analysis of bile from one animal only from each group. Results obtained from additional analysis of bile from cyp271/1
and cyp272/2 mice were similar.
c p , 0.001, Student’s t test.
FIG. 4. Electrospray mass spectrometry of unhydrolyzed bile from a cyp271/1 and a cyp272/2 mouse. For experimental details, see
“Experimental Procedures.”
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hydroxylase in the liver (45). The concentration of circulating
7a-hydroxycholesterol was found to be 4–10-fold higher in the
cyp272/2 mice than in the two other genotypes (Table III).
That the cholesterol 7a-hydroxylase was up-regulated was
also confirmed by RNA blot analysis (data not shown). Thus the
ratio between the cyp7 and the actin mRNA was 2.7 6 0.5 (n 5
7) and 0.3 6 0.1 (n 5 6), in the livers of the cyp272/2 and the
cyp271/1 mice, respectively.
Cholesterol Synthesis—The reduced synthesis of bile acids in
the knock-out mice leads to reduced absorption of cholesterol,
which may lead to a compensatory increased synthesis. The
up-regulation of the cholesterol 7a-hydroxylase can also be
expected to lead to a secondary up-regulation of the rate-lim-
iting enzyme in cholesterol synthesis, HMG-CoA reductase
(46–48). In accordance with this, the hepatic levels of HMG-
CoA reductase mRNA was found to be 2–3-fold higher in the
knock-out mice than in the wild type (data not shown).
It is well documented that up-regulation of HMG-CoA reduc-
tase in the liver leads to increased levels of the precursor
lathosterol in the circulation (49). The level of lathosterol in the
circulation of three cyp272/2 mice was found to be 769 6 56
ng/ml (mean 6 S.E.) as compared with 231 6 90 ng/ml in three
cyp271/1 mice (p , 0.01, Student’s t test).
Circulating Levels of Fat-soluble Vitamins—As shown in Ta-
ble IV, the levels of vitamin A were about the same in the wild
type and in the cyp272/2 mice. Vitamin E levels in the cyp272/2
mice were somewhat lower than those of the wild type, but this
difference was not significant from a statistical point of view.
Levels of 25-hydroxyvitamin D were clearly higher in the
cyp272/2 mice than in the wild type (p , 0.01, Student’s t test).
Levels of 1,25-dihydroxyvitamin D were similar in the two
groups of mice.
Circulating Levels of Cholesterol and Triglycerides, Fecal
Excretion of Cholesterol—The circulating levels of cholesterol
(total cholesterol) varied between 1.5 and 3.0 mmol/liter in both
the wild type and the cyp272/2 mice on a normal diet. The
triglyceride levels in the three groups of mice varied between
0.2 and 0.8 mmol/liter.
The very low production of bile acids in the cyp272/2 mice
could be expected to result in increased fecal excretion of fat in
feces. The excretion of cholesterol was 3.4 6 0.3 (n 5 5) and
FIG. 5. Gas chromatogram obtained in a gas chromatography-mass spectrometry analysis of methylated and trimethylsilyl
ether-derivatized hydrolyzed extract of feces from a control mouse (cyp271/1) and a sterol 27-hydroxylase-deficient mouse
(cyp272/2). An equal amount of a daily excretion of feces was analyzed. I, lithocholic acid (3a-hydroxy-5b-cholanoic acid); II, isomer of a
3,12-dihydroxy-5b-cholanoic acid; III, deoxycholic acid (3a,12a-dihydroxy-5b-cholanoic acid); IV, a-muricholic acid (3a,6b,7a-trihydroxy 5b-
cholanoic acid); V, chenodeoxycholic acid (3a,7a-dihydroxy-5b-cholanoic acid); VI, cholic acid, (3a,7a,12a-trihydroxy-5b-cholanoic acid); VII, isomer
of a 3,12-dihydroxycholanoic acid; VIII, b-muricholic acid (3a,6b,7b-trihydroxy-5b-cholanoic acid; IX, v-muricholic acid (3a,6a,7b-trihydroxy-5b-
cholanoic acid); X, allo-v-muricholic acid, (3a,6a,7b-trihydroxy-5a-cholanoic acid).
TABLE II
Content of 7a-hydroxycholesterol in different organs





Liver 70 70 880
Kidney 62 63 377
Brain 54 28 249
TABLE III
Serum levels of some oxysterols in cyp1/1, cyp271/2,
and cyp272/2 mice





7a-Hydroxycholesterol 0.47 6 0.20 0.40 6 0.16 2.2 6 1.0
24-Hydroxycholesterol 0.02 6 0.00 0.02 6 0.00 0.03 6 0.03
27-Hydroxycholesterol 0.08 6 0.01 0.04 6 0.00 ,0.001
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1.9 6 0.2 mg/g (n 5 5) feces in the cyp272/2 and the cyp271/1
mice, respectively (p 5 0.05).
Levels of Cholestanol in Liver and Circulation—The ratio
between cholestanol and cholesterol was found to be 0.009 6
0.003, 0.011 6 0.003, and 0.016 6 0.006 in livers of the
cyp272/2, the cyp271/2, and the cyp271/1 mice, respectively.
Similar ratios were found in the circulation (not shown).
DISCUSSION
Consequences of the Lack of Sterol 27-Hydroxylase for Bile
Acid Synthesis—It is evident that a lack of the sterol 27-
hydroxylase has a more dramatic effect on production of bile
acids in mice than in humans. In patients with CTX the en-
zyme deficiency leads to a markedly reduced production of
chenodeoxycholic acid, whereas production of cholic acid is
normal or almost normal (10). The latter production is most
probably due to a microsomal 25-hydroxylase, active on 5b-
cholestane-3a,7a,12a-triol. The product 5b-cholestane-
3a,7a,12a,25-tetrol can be converted into cholic acid in a path-
way involving cleavage of acetone from the steroid side chain
(cf. above). The microsomal 25-hydroxylase is considerably
more active in human liver microsomes than in rat liver mi-
crosomes (51). In preliminary experiments the activity of this
enzyme was found to be about equal in rat and mouse liver. The
relatively low activity of the microsomal 25-hydroxylase in
mouse liver may thus explain why cyp272/2 mice are unable to
compensate for the lack of the sterol 27-hydroxylase by forma-
tion of bile acids through the alternative 25-hydroxylase
mechanism.
The small amounts of bile acids found in the cyp272/2 mice
might in part have been formed by the sterol 25-hydroxylase
pathway. Small amounts of bile alcohols were found in bile and
urine of cyp272/2 mice, and trace amounts of 5b-cholestane-
3a,7a,12a,25-tetrol could in fact be identified in feces of one of
the cyp272/2 mice.
In contrast to humans, rat liver contains a microsomal 26-
hydroxylase that is able to catalyze 26-hydroxylation of 5b-
cholestane-3a,7a,12a-triol (52). The product, 5b-cholestane-
3a,7a,12a,26-tetrol, being an isomer to 5b-cholestane-
3a,7a,12a,27-tetrol, might well be further converted into cholic
acid. Whether or not mouse liver microsomes contain such a
26-hydroxylase is not known with certainty. If such enzyme
activity exists, it may also explain part of the small amounts of
bile acids formed in the cyp272/2 mice. At the present state of
knowledge, we also cannot exclude that a sterol 24-hydroxylase
present in the brain (53) may be of some importance for the
conversion of cholesterol into bile acids in the cyp272/2 mice.
In accordance with the findings in patients with CTX, the
lack of the sterol 27-hydroxylase resulted in a compensatory
up-regulation of the cholesterol 7a-hydroxylase in the cyp272/2
mice. The circulating levels of 7a-hydroxycholesterol were thus
markedly elevated, and RNA blot analysis showed about 9-fold
increased concentrations of cholesterol 7a-hydroxylase mRNA
in the liver.
Formation of Cholestanol in cyp272/2 Mice—One of the
characteristics of CTX is an increased production of cholestanol
(10). This production is most probably linked to the accumula-
tion of 7a-hydroxylated intermediates in bile acid biosynthesis,
in particular 7a-hydroxy-4-cholesten-3-one. Conversion of 7a-
hydroxy-4-cholesten-3-one into cholestanol requires a critical
dehydration of this steroid by a microsomal dehydratase (54).
We have shown that the activity of this enzyme is severalfold
higher in human liver than in rat liver (54). In preliminary
experiments we showed that the activity of this dehydratase is
about similar in rat and in mouse liver. The relatively low
activity of this enzyme may thus explain why the cyp272/2
mice did not have higher levels of cholestanol than the
cyp271/1 mice.
Consequences of the Lack of Sterol 27-Hydroxylase for Trans-
port of Cholesterol from Peripheral Tissues—Patients with CTX
are known to develop premature atherosclerosis despite nor-
mal circulating levels of cholesterol (10). It has been suggested
that this could be a consequence of the lack of the sterol 27-
hydroxylase in macrophages in these patients (1–3). The sterol
27-hydroxylase is thus able to eliminate cholesterol from
macrophages by converting it into 27-hydroxycholesterol and
3b-hydroxy-5-cholestenoic acid that are easily excreted from
the cells. The general importance of this mechanism is reflected
in the very high levels of sterol 27-hydroxylase in human
macrophages (1, 2) and in the high flux of 27-oxygenated C27
steroids from extrahepatic tissues to the liver in humans (3).
The latter flux is likely to be of similar magnitude in mice and
in humans, as judged from the relatively high levels of circu-
lating 27-hydroxycholesterol (Table III). Under the conditions
employed, however, the cyp272/2 mice did not produce visible
xanthomas or atheromas. At the present state of knowledge, it
cannot be excluded that the accumulation of cholestanol and/or
C27 bile alcohols that are seen in CTX patients but not in the
cyp272/2 mice is the most critical factor for the development of
xanthomas and atheromas in CTX patients.
Consequences of the Lack of the Sterol 27-Hydroxylase for
Cholesterol Synthesis and Homeostasis—27-Hydroxycholes-
terol is known to be a potent down-regulator of HMG-CoA
reductase in cultured cells (7, 8). The importance of this mech-
anism is, however, controversial. If the sterol 27-hydroxylase
has a key role in cholesterol homeostasis, a lack of the enzyme
would be expected to be associated with a markedly increased
synthesis of cholesterol and elevated circulating levels of cho-
lesterol in the circulation. CTX patients are, however, known to
have normal circulating levels of cholesterol, and this was
found to be the case also in the present cyp272/2 mice. Patients
with CTX are known to have an overall increased cholesterol
synthesis, most probably secondary to the up-regulated choles-
terol 7a-hydroxylase (10). That the increased cholesterol syn-
thesis in the present sterol 27-hydroxylase-deficient mice is
secondary to the up-regulated cholesterol 7a-hydroxylase
seems likely in view of the finding that the synthesis of the
latter enzyme was increased much more than the synthesis of
HMG-CoA reductase. The up-regulated hepatic HMG-CoA re-
ductase may be a compensation for a consumption of choles-
terol due to the highly up-regulated cholesterol 7a-hydroxylase
(cf. Ref. 48).
Consequences of the Lack of the Sterol 27-Hydroxylase for
Metabolism of Vitamin D—Sterol 27-hydroxylase is able to
25-hydroxylate vitamin D (4). Since the liver mitochondrial
fraction of a patient with CTX has been found to possess some
25-hydroxylase activity toward vitamin D (55) and since the
microsomal fraction of liver homogenate also contains this ac-
tivity (6), the relative importance of the sterol 27-hydroxylase
for this reaction is difficult to evaluate. Reduced bone density
and reduced circulating levels of 25-hydroxyvitamin D and
24,25-dihydroxyvitamin D have also been reported in some
TABLE IV
Levels of fat-soluble vitamins or vitamin metabolites in the circulation
of wild type and cyp272/2 mice




Vitamin A (mmol/liter) 1.2 6 0.1 1.3 6 0.3
Vitamin E (mmol/liter) 9.7 6 2.0 6.0 6 1.9
25-Hydroxyvitamin D3 (mg/liter) 42 6 7 106 6 9
1,25-Dihydroxyvitamin D3 (mg/liter) 0.13 6 0.04 0.14 6 0.03
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CTX patients (23). Other patients have normal levels of 25-
hydroxyvitamin D, however (10).2 A serum pool from three
cyp272/2 mice had somewhat higher concentrations of 25-hy-
droxyvitamin D than a serum pool from three cyp271/1 mice. In
view of this, sterol 27-hydroxylase seems to be of little impor-
tance for 25-hydroxylation of vitamin D in mice. Recently it was
shown that sterol 27-hydroxylase has some 1a-hydroxylase
activity toward 25-hydroxyvitamin D3 (5). The circulating con-
centration of 25-dihydroxyvitamin D was, however, somewhat
higher in cyp272/2 mice than in cyp271/1 mice, whereas the
corresponding concentrations of 1,25-dihydroxyvitamin D were
similar in the two groups of mice. Thus it seems less likely that
sterol 27-hydroxylase is of importance in formation of 25-hy-
droxyvitamin D and 1,25-dihydroxyvitamin D in this species.
Consequences of the Reduced Formation of Bile Acids in
cyp272/2 Mice—Surprisingly, the markedly reduced produc-
tion of bile acids in the cyp272/2 mice was not associated with
any symptoms of malabsorption. The content of cholesterol and
fatty acids in feces was thus only moderately increased, and the
circulating levels of the fat-soluble vitamins A and E were
normal or only slightly reduced. It is interesting to compare
this situation with the situation in mice with a disruption of the
cyp7 (56). During the first 4 weeks of life, these mice had a
severe fat malabsorption with very low circulating levels of
25-hydroxyvitamin D3 and vitamin E and high content of lipids
in stool. After this period a normalization occurred, most prob-
ably due to induction of an oxysterol 7a-hydroxylase in the
liver. The adult cyp272/2 mice had an excretion of bile acids in
stool that was reduced by about 80% as compared with the wild
type. Evidently, this low degree of production of bile acids is
sufficient to prevent fat malabsorption.
Is the Cyp 272/2 Mouse Suitable as an Animal Model for
CTX?—It is evident that a disruption of the cyp272/2 gene in a
mouse on a normal diet does not lead to the metabolic, neuro-
logic, and vascular disturbances found in patients with a cor-
responding genetic defect. The compensatory mechanism in
humans (activation of the 25-hydroxylase pathway) and the
consequences of accumulation of bile acid intermediates (accu-
mulation of cholestanol) were not observed in the cyp272/2
mice. It is possible that the enzymatic defect in the cyp272/2
mice may be more important when increasing the dietary in-
take of cholesterol. In preliminary experiments an increased
death rate was observed for cyp272/2 mice when fed an athero-
genic diet. No explanation for this finding has been obtained
thus far, however. Experiments with the goal of clarifying the
importance of the sterol 27-hydroxylase in mice with additional
genetic defects and under different dietary conditions are now
in progress.
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5. Axén, E., Postlind, H., Sjöberg, H., and Wikvall, K. (1994) Proc. Natl. Acad.
Sci. U. S. A. 91, 10014–10018
6. Björkhem, I., Hansson, R., Holmberg, I., and Wikvall, K. (1979) Biochem.
Biophys. Res. Commun. 90, 615–622
7. Javitt, N. B. (1990) J. Lipid Res. 31, 1527–1533
8. Lund, E., and Björkhem, I. (1995) Acc. Chem. Res. 28, 241–249
9. Lund, E., Breuer, O., and Björkhem, I. (1992) J. Biol. Chem. 267, 25092–25097
10. Björkhem, I., and Muri-Boberg, K. (1994) in The Metabolic Basis of Inherited
Diseases (Scriver, C. R., Beaudet, A. L., Sly, W. S., and Valee, D., eds) pp.
2073–2100, McGraw-Hill Inc., New York
11. Cali, J. J., Hsieh, C. L., Francke, U., and Russell, D. W. (1991) J. Biol. Chem.
266, 7779–7783
12. Leitersdorf, E., Reshef, A., Meiner, V., Levitzki, R., Pressman-Schwartz, S.,
Dann, E. J., Berkman, N., Cali, J. J., Klapholz, L., and Berginer, V. M.
(1993) J. Clin. Invest. 91, 2488–2496
13. Meiner, V., Marais, D. A., Reshef, A., Björkhem, I., and Leitersdorf, E. (1994)
Hum. Mol. Genet. 3, 193–194
14. Kim, K. S., Kubota, S., Kuriyama, M., Fujiyama, J., Björkhem, I., Eggertsen,
G., and Seyama, Y. (1994) J. Lipid Res. 35, 1031–1039
15. Meiner, V., Meiner, Z., Reshef, A., Björkhem, I., and Leitersdorf, E. (1994)
Neurology 44, 288–290
16. Reshef, A., Meiner, V., Berginer, V. M., and Leitersdorf, E. (1994) J. Lipid Res.
35, 478–483
17. Leitersdorf, E., Safadi, R., Meiner, V., Reshef, A., Bjorkhem, I., Friedlander,
Y., Morkos, S., and Berginer, V. M. (1994) Am. J. Hum. Genet. 55, 907–915
18. Segev, H., Reshef, A., Clavey, V., Delbart, C., Routier, G., and Leitersdorf, E.
(1995) Hum. Mol. Genet. 95, 238–240
19. Watts, G. F., Mitchell, W. D., Bending, J. J., Reshef, A., and Leitersdorf, E.
(1996) Q. J. Med. 89, 55–63
20. Nakashima, N., Sakai, Y., Sakai, H., Yanese, T., Haji, M., Umeda, F., Koga, S.,
Hoshita, T., and Nawata, H. (1994) J. Lipid Res. 35, 663–668
21. Duane, W. E., Björkhem, I., Hamilton, J. N., and Mueller, S. M. (1988)
Hepatology 8, 613–618
22. Duane, W. E., Pooler, P. A., and Hamilton, J. N. (1988) J. Clin. Invest. 82,
82–85
23. Berginer, V. M., Salen, G., and Shefer, S. (1989) Neurol. Clin. 7, 55–64
24. Usui, E., Noshiro, M., and Okuda, K. (1990) FEBS Lett. 262, 135–138
25. Su, P., Rennert, H., Shayiq, R. M., Yamamoto, R., Zheng, Y. M., Addya, S.,
Strauss, J. F., III, and Avadhani, N. G. (1990) DNA Cell Biol. 9, 657–665
26. Tybulewicz, V. L., Crawford, C. E., Jackson, P. K., Bronson, R. T., and
Mulligan, R. C. (1991) Cell 65, 1153–1163
27. Beck, E., Ludwig, G., Auerswald, E. A., Riess, B., and Schaller, H. (1982) Gene
(Amst.) 19, 327–336
28. Cali, J. J., and Russell, D. W. (1991) J. Biol. Chem. 266, 7774–7778
29. Andersson, S., Davis, D. L., Dahlback, H., Jornvall, H., and Russell, D. W.
(1989) J. Biol. Chem. 264, 8222–8229
30. Gonzales, F. J. (1989) Pharmacol. Rev. 40, 243–288
31. Piedrahita, J. A., Zhang, S. H., Hagaman, J. R., Oliver, P. M., and Maeda, N.
(1992) Proc. Natl. Acad. Sci. U. S. A. 89, 4471–4475
32. McMaster, G. K., and Carmichael, G. G. (1977) Proc. Natl. Acad. Sci. U. S. A.
74, 4835–4838
33. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A
Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring
Harbor, NY
34. Gehring, M., Shiels, B. R., Northemann, W., de Bruijn, M. H. L., Kan, C. C.,
Chain, A. C., Noonan, D. J., and Fey, C. C. (1987) J. Biol. Chem. 262,
446–454
35. Catagnani, G. L., and Bieri, J. G. (1983) Clin. Chem. 29, 708–712
36. Belsey, R., Clark, M. B., Bernat, M., Glowacki, J., Holick, M., DeLuca, H. F.,
and Potts, J. T. (1974) Am. J. Med. 57, 50–56
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